Audentes Therapeutics Cultura da Companhia

Mr. Thomas P. Soloway, also known as Tom, has been the Chief Financial Officer and Senior Vice President of Audentes Therapeutics, Inc. since September 2015. Mr. Soloway has more than 20 years of experience in operations, corporate finance and venture capital related to the life sciences industry. He served as the Chief Financial Officer of Ascendis Pharma A/S since January 2014 and also served as its Senior Vice President, Executive Director and Member of Executive Board. Mr. Soloway served as the Chief Operating Officer and Executive Vice President of Transcept Pharmaceuticals, Inc. from April 04, 2013 to December 31, 2013. Mr. Soloway served as Chief Financial Officer of Transcept Pharmaceuticals, Inc. from April 4, 2012 to June 25, 2012. He served as the Senior Vice President of Operations at Transcept Pharmaceuticals, Inc. since July 2003 and November 2005, respectively. Mr. Soloway also served as Senior Vice President and Chief Operating Officer of Transcept Pharmaceuticals, Inc., where he oversaw project planning, manufacturing, pharmaceutical sciences, legal, human resources, regulatory and corporate communications. He joined TPI as Co-Founder in 2002. Prior to joining TPI, he served as Principal Partner at Montreux Equity Partners, Montreux Equity Partners IV, L.P., Montreux Equity Partners II, L.P. and Montreux Equity Partners III, L.P. Prior to, he served as the Chief Financial Officer for RespondTV. Prior to joining Montreux, he managed the start-up of a home medical equipment division at Hi-Tech Healthcare, an entrepreneurial venture dedicated to delivering high quality home health services. Mr. Soloway served as a Director of Entelos, Inc. since May 2010. Mr. Soloway holds a Masters of Business Administration from Georgetown University and a Bachelors of Science in Entrepreneurial Studies from the University of Southern California.

Ms. Natalie C. Holles has been Chief Operating Officer and Senior Vice President of Audentes Therapeutics, Inc. since August 2015. Ms. Holles served as Senior Vice President of Corporate and Business Development at Hyperion Therapeutics, Inc. from July 2013 to May 2015. She served as an Executive Vice President of Corporate Development at Immune Design, Inc., a leading cancer immunotherapy company based in Seattle. Ms. Holles provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies from 2010 to 2013. She served as Vice President of Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012). She held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc. She began her career in the industry as a Marketing Planning Associate at Genentech, Inc. She has more than 15 years of corporate development, strategic planning and commercial experience, gained in a range of therapeutic areas and with a focus on orphan diseases. She was a Howard Hughes Medical Institute Predoctoral Fellow. Ms. Holles received her M.A. in Molecular, Cellular and Developmental Biology from the University of Colorado and her A.B. in Human Biology from Stanford University.

Dr. John T. Gray, Ph.D has been the Chief Scientific Officer and Senior Vice President at Audentes Therapeutics, Inc. since May 8, 2017 and served as its Senior Vice President of Research & Development since December 2015 and served its Vice President of Research and Development from July 2014 to December 2015. Dr. Gray joined Audentes with over 20 years of experience designing genetic therapies and vaccines and developing manufacturing processes for those products. For 11 years prior to joining Audentes, Dr. Gray was the Director of Vector Production and Development at St. Jude Children's Research Hospital where he led a team devoted to advancing the gene therapy vector science. In the area of lentiviral vector production, his team derived the GPRG stable cell line, the first such line to be used to successfully produce an HIV-based vector tested in a human clinical trial (for treatment of X-linked Severe Combined Immunodeficiency). Prior to joining St. Jude Children's Research Hospital in 2003, Dr. Gray was a researcher in the laboratory of Dr. Richard Mulligan. He also contributed significantly to the Hemophilia B gene therapy project, for which he designed the self-complementary AAV Factor IX vector expression cassette and developed the production process used to manufacture the first two batches of clinical vector. During his tenure of St. Jude, which began in 2003, Dr. Gray also worked on Chimeric Antigen Receptor modified cell therapy, lysosomal storage disorder gene therapy and multiple hematopoietic stem/progenitor cell gene therapy projects. Prior to joining St. Jude, Dr. Gray served as the assistant director of the Harvard Gene Therapy Initiative and prior to that, worked at Pfizer Animal Health designing bacterial and viral vectors for vaccine applications. Dr. Gray has a Bachelor of Arts degree in Biochemistry from the University of California, Berkeley and a Ph.D. degree in Biochemistry from the University of Colorado, Boulder.

Mary Newman serves as the Senior Vice President, Regulatory Affairs of Audentes Therapeutics. Mary started at Audentes Therapeutics in October of 2014. Mary currently resides in San Francisco Bay Area.

Tom Soloway serves as the Senior Vice President and Chief Financial Officer of Audentes Therapeutics. Tom started at Audentes Therapeutics in October of 2015. Tom currently resides in San Francisco Bay Area.

Jason Barker serves as the Vice President, Finance of Audentes Therapeutics. Jason started at Audentes Therapeutics in February of 2015. Jason currently resides in San Francisco Bay Area.

Megan Baierlein serves as the VP of Program Management of Audentes Therapeutics. Megan started at Audentes Therapeutics in July of 2018. Megan currently resides in the San Francisco Bay Area.